Table 1.
Brief overview of current treatment options available for COVID 19 and multisystem inflammatory syndrome in children and adults (14, 25, 28, 32, 33).
| Drug | Indication | Notes |
|---|---|---|
| Remdesivir (antiviral) |
Hospitalized patients with COVID19 who require supplemental oxygen | Remdesivir is the only drug FDA approved for the treatment of COVID 19. It is approved for patients ≥12 years and weigh ≥40 kg but is also available for younger children (and those weighing <40 and >3.5 kg) through an FDA EUA |
| Glucocorticoids (immunomodulator) | Hospitalized patients COVID19 who require supplemental oxygen First line agent for MIS (C/A) |
Not specifically FDA approved for COVID 19 infection or MIS (C/A). |
| IVIG (immunomodulator) | First line agent for MIS (C/A) | Not specifically FDA approved for COVID 19 infection or MIS (C/A). |
| Tocilizumab (IL-6 receptor antagonist) | May be considered for MIS refractory to IVIG and/or glucocorticoids | Not specifically FDA approved for COVID 19 infection or MIS (C/A). |
| Anakinra (IL-1 receptor antagonist) | Not specifically FDA approved for COVID 19 infection or MIS (C/A). | |
| Baricitinib (JAK inhibitor) | Available under EUA for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized patients ≥ 2 years of age requiring supplemental oxygen, IMV, or ECMO, in combination with remdesivir | |
| Casirivimab plus imdevimab (SARS-CoV-2 neutralizing antibody) | Available under EUA for non-hospitalized patients ≥12 years of age weighing ≥40 kg with mild to moderate COVID-19 who are at high risk for progressing to severe disease and/or hospitalization | |
| Bamlanivimab (SARS-CoV-2 neutralizing antibody) | ||
| Investigational drugs/treatment | ||
| Anti-SARS Cov-2 T cell infusions for COVID 19 (BATIT) (SARS-CoV2-specific T cells) NCT04401410 |
Hospitalized COVID19 patients with high risk of progression to mechanical ventilation. | |
| Convalescent plasma (passive immune therapy) | Hospitalized patients with COVID19 infection, indications vary per trial | |
COVID 19, coronavirus disease 2019; FDA, Food and Drug Administration; EUA, Emergency Use Authorization; Kg, Kilogram; MIS (C/A), multisystem inflammatory syndrome (children/adults); IVIG, intravenous immune globulin; IL, interleukin; JAK, Janus kinase; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation; SARS-CoV-2, severe acute respiratory syndrome associated coronavirus.